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In a critical review of Richard Epstein’s book Over-dose: How Excessive Government Regulation StiflesPharmaceutical Innovation, Arnold Relman (The New
Republic, July 30) criticizes drug companies for their
hypocrisy. Contrasting the companies’ message to stock-
holders with their message to the larger world, he
quotes Pfizer President Jeffrey Kindler’s statement that
his goal is “to create and sustain value for shareholders”
and the company’s advertising slogan, “Working for a
healthier world.” Relman writes, “To hear these firms
tell it, making money is hardly of
interest to them, because their primary
concern is the public’s welfare.”
Although Relman has written
about the drug industry for years, this
statement shows a profound misunder-
standing of how profits in that indus-
try, or in any industry, work. Contrary
to what Relman says, the main way for
a drug company to make money is to
promote the health of its customers.
But don’t drug companies make
money off our sickness? Yes, just as
the food industry makes money off our hunger. But the
food industry doesn’t make money by keeping us hun-
gry; it makes money by feeding us. Similarly, drug com-
panies and other health-care providers make money
not by keeping us sick, but by making us well.
One day in the fall of 1995 I got very sick quickly. I
was unable to keep liquids in my body, and I lost almost
ten pounds in less than 24 hours. My wife took me to
the Community Hospital of the Monterey Peninsula.
There I rested in a quiet private room in a clean, won-
derfully comfortable bed, while an intravenous device
pumped about eight pounds of fluid into my body. I
slept 22 of the next 24 hours. The bill for one day,
slightly over $2,000, was mostly covered by insurance.
But had I been required to pay the whole amount out
of my own pocket, I would have gladly done so. My
doctor later told me that every cell in my body had
been damaged and that, had I not gone to the hospital
that evening, I might have died. For the next few
months, whenever I drove by that hospital I cheered.
The men and women working there didn’t know me,
but spent their best energy making me
well and, maybe, saving my life. How-
ever much they like helping people
heal, they would not have been there if
someone hadn’t paid them.They made
money off my sickness. Bless them.
The insight that sellers make money
by giving customers what they want is
not new. One of the most famous
quotes in Adam Smith’s The Wealth of
Nations is his statement that it’s not
from the benevolence of the butcher,
the baker, or the brewer that we expect
our dinner, but from their regard for their own self-
interest. It’s striking that more than two centuries after
this insight became famous, a major political magazine
that regards itself as a sophisticated commentator on the
issues of the day publishes an article that parades such
economic ignorance.
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I would like to live to age 100 and to be reasonably
healthy up to that age. I would like my friends to do so
also.That’s unlikely, but what would make it more like-
ly is for drug companies to figure out cures for the dis-
eases that would otherwise kill many of us: heart disease,
cancer, diabetes, Parkinson’s, and Alzheimer’s, to name a
few. What motivates drug companies is the large rev-
enue they can earn by developing drugs that cure dis-
eases and save lives.Think about your family. I bet you
can think of family members who were seriously ill
who could have avoided illness had these innovations
existed earlier. It’s true of my family. My father had
polio in both legs in 1944. My sister had polio in 1952.
Unfortunately for them, the drug company Parke-Davis
was unable to produce high-quality Salk vaccine until
February 1954. Now we take for granted that we won’t
get polio—and that’s thanks to a drug company that
wanted to make money for its share-
holders and thanks to some scientists
who wanted to make money for
themselves and their families.
Because of his distrust of the
profit motive, Relman wants the
government to continue regulating
and, indeed, regulate more, the
actions of drug companies. What 
is his argument for regulation?
Nowhere in his lengthy review of
Epstein’s book on drug-industry regulation does Rel-
man actually make an argument. Instead, he settles for
quoting authority. Take Epstein’s claim that Food and
Drug Administration (FDA) regulations keep drugs off
the market, sometimes for years and sometimes forever.
Relman dismisses this argument rather than refuting it.
Relman writes:
But this “logjam” [preventing new drugs] is pure
conjecture, because there is nothing to support such
a notion. There was once a problem with delays in
reviewing and approving new drugs, but much has
been done through legislation and administrative
reforms at the FDA to expedite and to simplify the
process of drug approval.The FDA now moves with
greater alacrity than most analogous agencies in
advanced countries.
Notice Relman’s language. Epstein’s idea is not an
idea but a “notion.” And Relman regards Epstein’s idea
as pure conjecture rather than something that has been
backed up by logical argument and ample evidence.
The argument for Epstein’s claim is straightforward: all
else equal, the more requirements the government puts
in the way of drug development, the less development
will occur. By starting, in 1962, to require drug compa-
nies to show that a drug is effective (the requirement
that they be safe has existed since 1938), the FDA added
to the delay between innovation and availability to con-
sumers.The evidence is also ample. In 1974, University
of Chicago economist Sam Peltzman estimated that the
efficacy requirement added a minimum of two years to
the drug-approval process. Later studies by economists
and pharmacologists found similar results. (See www.
fdareview.org/harm.shtml.)
Who Decides?
Some might argue that it’s worth-while to delay drugs by years to
make sure they’re effective. But ask
someone who’s dying whether that’s a
worthwhile tradeoff.
Relman writes, “Almost everyone
familiar with our health care system—
including the leaders of the industry!—
agrees that prescription drugs should
be regulated.” So let’s get this straight. Relman seems to
totally distrust the effect of the profit motive on drug
companies’ behavior. Somehow, though, we’re not sup-
posed to question one part of the drug companies’
behavior, their support for regulation of their own
industry. But why wouldn’t they support regulation for
the same reason airline executives supported regulation
of their industry—to restrict competition? Relman
ignores this question.
The view that the profit motive and health of cus-
tomers are antithetical is simply incorrect. Drug compa-
nies look especially good when one considers the
regulatory alternatives. Given a choice between trusting
a government agency whose employees are paid the
same whether or not they approve drugs or trusting a
drug company that makes money by making me
healthy, I would choose the latter.
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The view that the
profit motive and
health of customers
are antithetical is
simply incorrect.
